Regeneron Pharmaceuticals (NASDAQ:REGN) Given Sector Perform Rating at Royal Bank Of Canada

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “sector perform” rating restated by Royal Bank Of Canada in a report issued on Tuesday, Benzinga reports. They currently have a $737.00 price target on the biopharmaceutical company’s stock. Royal Bank Of Canada’s target price indicates a potential upside of 0.23% from the stock’s current price.

Other equities research analysts have also issued research reports about the stock. Piper Sandler cut their price target on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a report on Thursday, July 9th. Truist Financial increased their target price on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Cantor Fitzgerald raised their target price on Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Guggenheim boosted their price target on Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a “buy” rating in a report on Monday, August 3rd. Finally, Benchmark raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target for the company in a research report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $809.50.

Regeneron Pharmaceuticals Trading Up 0.1%

NASDAQ:REGN traded up $0.51 during trading hours on Tuesday, reaching $735.32. The company’s stock had a trading volume of 379,429 shares, compared to its average volume of 829,282. The firm has a market capitalization of $75.71 billion, a price-to-earnings ratio of 18.17, a PEG ratio of 1.49 and a beta of 0.16. The firm has a 50-day simple moving average of $786.71 and a 200-day simple moving average of $720.83. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34. Regeneron Pharmaceuticals has a 1 year low of $541.00 and a 1 year high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. During the same quarter in the prior year, the firm posted $12.81 earnings per share. The business’s quarterly revenue was up 16.7% compared to the same quarter last year. Research analysts expect that Regeneron Pharmaceuticals will post 44.25 EPS for the current fiscal year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,215 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the sale, the executive vice president directly owned 13,134 shares in the company, valued at approximately $11,163,900. This trade represents a 8.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $340,000.00. Following the transaction, the director directly owned 603 shares in the company, valued at approximately $512,550. The trade was a 39.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 3,946 shares of company stock worth $3,302,458 in the last three months. Insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Versant Capital Management Inc boosted its holdings in shares of Regeneron Pharmaceuticals by 55.2% in the third quarter. Versant Capital Management Inc now owns 534 shares of the biopharmaceutical company’s stock worth $405,000 after buying an additional 190 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 0.6% during the 2nd quarter. Envestnet Asset Management Inc. now owns 109,838 shares of the biopharmaceutical company’s stock worth $68,488,000 after acquiring an additional 686 shares during the last quarter. Andra AP fonden boosted its stake in shares of Regeneron Pharmaceuticals by 583.2% during the 2nd quarter. Andra AP fonden now owns 28,912 shares of the biopharmaceutical company’s stock worth $18,028,000 after acquiring an additional 24,680 shares during the last quarter. State Street Corp grew its position in shares of Regeneron Pharmaceuticals by 3.6% during the 2nd quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company’s stock valued at $3,014,621,000 after acquiring an additional 170,210 shares during the period. Finally, Tidal Investments LLC lifted its position in Regeneron Pharmaceuticals by 10.7% during the second quarter. Tidal Investments LLC now owns 43,896 shares of the biopharmaceutical company’s stock valued at $27,371,000 after purchasing an additional 4,244 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Trending Headlines about Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Expanded Sanofi alliance provides substantial near-term and potential long-term value. Regeneron will receive $1 billion upfront and could receive up to $7 billion in milestone payments for adding four next-generation, long-acting antibodies targeting type 2 inflammation. The companies will share development and commercialization costs and future profits, potentially strengthening Regeneron’s immunology pipeline beyond Dupixent. Regeneron and Sanofi Expand Global Alliance
• Positive Sentiment: Trevogrumab delivered promising obesity-treatment data. In the Phase 2 COURAGE trial, the antibody prevented approximately 70% of the lean-mass loss associated with semaglutide in an MRI substudy. The results support a potential combination therapy addressing a key side effect of GLP-1 weight-loss drugs. Phase 2 COURAGE Trial Results
• Positive Sentiment: Analysts became more constructive. Jefferies raised its price target to $930 from $870 and maintained a buy rating, while Argus upgraded REGN to buy with an $850 target. These actions signal confidence in the company’s pipeline and valuation. Regeneron Analyst Price Target Changes
• Neutral Sentiment: Ubamatamab showed encouraging but preliminary efficacy in ovarian cancer. The treatment produced a 73% objective response rate and an 11-month median progression-free survival in 11 heavily pretreated patients with low-grade serous ovarian cancer. The small, early-stage dataset needs confirmation in larger studies. Ubamatamab Ovarian Cancer Results
• Negative Sentiment: The ovarian cancer report initially pressured the stock. Despite the high response rate, investors appeared concerned about the limited sample size, early development stage and uncertainty over whether the results will translate into regulatory approval or commercial revenue. RBC’s “sector perform” rating also provides a more cautious counterpoint to the bullish analyst actions. Regeneron Ovarian Cancer Trial Data

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.